Adults with type 2 diabetes with and without established cardiovascular disease assigned the SGLT2 inhibitor canagliflozin did not have an increased risk for below-the-knee amputation compared with patients assigned similar SGLT2 inhibitors or other antidiabetes therapies, according to findings from the OBSERVE-4D study. In a real-world analysis of more than 700,000 patients with type 2 diabetes, researchers also observed a substantial reduction in risk for hospitalization for heart failure — including patients with established CVD — a benefit noted in other SGLT2 inhibitor trials that suggests a possible class effect.
See original article:
OBSERVE-4D: No amputation risk with canagliflozin in type 2 diabetes